InvisiShield Technologies Ltd. is a biotechnology company developing intranasal preventive technology to prevent COVID-19 from all major current and potential future SARS-CoV-2 variants using our proprietary “capture and kill” technology. Our technology can be applied to other airborne pathogens, including influenza and RSV. InvisiShield’s COVID-19 intranasal preventive spray, also called IS101, was designed by a team of leading scientists and clinicians from both academia and industry with the goal of preventing infection of COVID-19’s causative virus SARS-CoV-2 in individuals and curbing forward spread of SARS-CoV-2 in our society. Our founders include Dr. Cheng Liu, President and CEO of Eureka Therapeutics, Inc., and Dr. Warner Greene, founding Director, and the Nick and Sue Hellmann Distinguished Professor of the Gladstone Institute of Virology and Immunology, a research center dedicated to pioneering scientific discovery in virology and immunology. We are based in Emeryville, California.

InvisiShield’s COVID-19 intranasal preventive spray (IS101) is designed to provide immediate protection against SARS-CoV-2 infection, regardless of a person’s vaccination or immune system status. IS101 binds SARS-CoV-2 and has a proprietary retention technology. It “captures and kills” all major current and potential future SARS-CoV-2 variants in the nasal cavity, the primary entry point of infection.

InvisiShield’s COVID-19 intranasal preventive spray was designed to capture and neutralize SARS-CoV-2 in the nasal cavity, the primary entry point for SARS-CoV-2 infection. Once sprayed into the nostrils, IS101 electrostatically interacts with native mucin proteins in the nasal passage, thereby coating the principal portal of viral entry as an “invisible shield”. When SARS-CoV-2 droplets or particles are inhaled through the nasal passage, IS101 “captures and kills” these viruses. IS101 has also been engineered with our proprietary technology to increase its retention time on respiratory mucosal surfaces to extend the duration of protection.

At the lowest dose of 200 μg, IS101 provided at least 10 hours of protection against infection in mice exposed to the highest viral load tested (10 million pseudotyped virus particles administered intra-nasally).

The purpose of InvisiShield’s COVID-19 intranasal preventive spray (IS101) is to provide immediate protection against SARS-CoV-2 infection, regardless of a person’s vaccination or immune system status. While vaccines and therapeutics have many benefits, they also have shortcomings. Vaccines have become less and less effective due to waning antibody neutralization and the emergence of immunoevasive variant viruses which caused the failure of vaccines to block “breakthrough” infections in vaccinated people, necessitating the development of booster shots that also target the new variants. Vaccines work poorly in the immunocompromised and cannot be administered to certain populations. Moreover, regardless of vaccination status, people who have been infected can experience a wide range of long-term health problems (Long COVID) which are still not well understood. Therapeutics, on the other hand, are given to people only after they have become infected by the virus.

Certain populations could benefit immediately from InvisiShield’s COVID-19 intranasal preventive spray. They include seniors, frontline health workers, the immunocompromised, athletes, and people who do not respond well to vaccines. InvisiShield’s COVID-19 intranasal preventive spray can also help protect from SARS-CoV-2 infection in situations with high risk for exposure, such as long-distance travel, classrooms, major social gathering events, as well as any indoor events with poor air circulation.

InvisiShield’s COVID-19 intranasal preventive spray is not commercially available at this time. Clinical trials are being planned to demonstrate safety and efficacy in humans before authorization from the U.S. Food and Drug Administration (FDA) is sought for commercial use.

Commercialization of InvisiShield’s COVID-19 intranasal preventive spray is currently being explored. Availability for over-the-counter use will depend on FDA approval.

InvisiShield Technologies is engaged with the FDA for an Investigational New Drug (IND) application to conduct clinical trials.

InvisiShield’s COVID-19 intranasal preventive spray will be initially manufactured in GMP facilities located in the U.S.

We envision InvisiShield’s COVID-19 intranasal preventive spray to complement vaccines, and other preventive measures such as face masks. A intranasal preventive spray adds to the arsenal of tools that can be used to fight the spread of COVID-19. It can be used to provide additional protection in conjunction with face masks or in situations in which face mask wearing is impractical.

Yes, our proprietary intranasal preventive spray platform can also be applied to other respiratory viruses, including influenza and RSV.

Eureka Therapeutics, Inc. is the original creator of InvisiShield’s (formerly known as InvisiMask) IS101 intranasal preventive spray. Eureka elected to separate its InvisiShield™ assets into InvisiShield Technologies Ltd. which will allow each company to focus on their respective core missions. Eureka. is a privately held clinical-stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical assets, ET140203 (ARYA1 for adults and ARYA2 for pediatrics) and ECT204 (ARYA3), in Phase I/II US trials in patients with advanced liver cancer.

For all inquiries, please e-mail: info@invisishield.tech